New treatment using humanized antibodies for a serious fungal infection
Humanized monoclonal antibodies to treat mucormycosis
['FUNDING_SBIR_2'] · VITALEX BIOSCIENCES, LLC · NIH-11042151
This study is looking at a new treatment for mucormycosis, a serious fungal infection that mainly affects people with weakened immune systems, by creating special antibodies that can better target the fungus and help improve recovery and survival rates.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VITALEX BIOSCIENCES, LLC (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-11042151 on ClinicalTrials.gov |
What this research studies
This research focuses on developing humanized monoclonal antibodies to treat mucormycosis, a severe fungal infection that primarily affects immunocompromised patients. The study aims to enhance the effectiveness of treatment by targeting specific proteins on the surface of the Mucorales fungi, which are responsible for the infection's ability to invade host tissues. By utilizing a humanized version of a previously successful mouse antibody, the research seeks to improve patient outcomes and reduce mortality rates associated with this life-threatening condition.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients who are immunocompromised due to conditions such as diabetes, neutropenia, or those undergoing corticosteroid treatment.
Not a fit: Patients with healthy immune systems or those not at risk for mucormycosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients suffering from mucormycosis, potentially lowering mortality rates.
How similar studies have performed: Previous research has shown promising results with monoclonal antibodies in treating fungal infections, indicating potential success for this novel approach.
Where this research is happening
IRVINE, UNITED STATES
- VITALEX BIOSCIENCES, LLC — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAZAR, GARY — VITALEX BIOSCIENCES, LLC
- Study coordinator: LAZAR, GARY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.